L'intérêt à découvert pour Zimmer Biomet Holdings donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Zimmer Biomet Holdings. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Zimmer Biomet Holdings (NYSE:ZBH) Stock, Rapport sur les intérêts à découvert

ZIMMER BIOMET HOLDINGS INC

Zimmer Biomet Holdings

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings Inc

Zimmer Biomet Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) on Monday agreed to acquire Monogram Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>) for an upfront payment of $4.04 per share, corresponding to an equity value of approximately $177 million and an enterprise value of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46388732/zimmer-biomet-announces-definitive-agreement-to-acquire-monogram-technologies-expanding-robotics-s" rel="noreferrer noopener">approximately $168 million</a>.
Monogram common stockholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share of common stock in cash if certain product development, regulatory, and revenue milestones are achieved through 2030.
Monogram&#8217;s semi- and fully autonomous robotic technologies are expected to add new and differentiated capabilities to expand Zimmer Biomet&#8217;s flagship ROSA&nbsp;Robotics platform and broad suite of navigation and enabling technologies.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45205381/hip-implant-maker-zimmer-biomet-cuts-annual-profit-forecast-on-paragon-28-deal-proposed-tariffs" rel="noreferrer noopener">Hip Implant Maker Zimmer Biomet Cuts Annual Profit Forecast On Paragon 28 Deal</a>
Monogram has developed a CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology, which <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44352653/exclusive-fda-approves-monogram-technologies-mbos-tka-system-for-knee-surgery" rel="noreferrer noopener">received FDA 510(k) clearance in March 2025</a> and is expected to be commercialized with Zimmer Biomet implants in early 2027.
Additionally, Monogram is developing a fully autonomous version of the technology that has the potential to significantly increase safety, efficiency, and outcomes, as well as have additional applications beyond TKA.
Upon closing the proposed transaction, Zimmer Biomet expects to have a clear pathway to become the first and only orthopedics company to offer a fully <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">autonomous surgical robot</a>.
&#8220;Monogram&#8217;s technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation,&#8221; said Ivan Tornos, Chairman, President, and Chief Executive Officer of Zimmer Biomet. &#8220;&#8230;Zimmer Biomet has the potential to become the first company to deliver fully autonomous capabilities and redefine both the standard of care and the future of orthopedic surgery.&#8221;
The ROSA platform, the cornerstone of Zimmer Biomet&#8217;s robotics offering, is rapidly approaching 2,000 installations worldwide.
Zimmer Biomet is investing in an R&amp;D pipeline that will produce several new products and software applications between now and 2027.
This includes ROSA Knee with OptimiZe, which has been submitted to the FDA, and 510(k) clearance is anticipated later this year, as well as ROSA Posterior Hip and the full commercial launch of ROSA Shoulder.
Zimmer Biomet plans to fund the proposed transaction using cash on the balance sheet and other available debt financing sources.
Zimmer Biomet believes this proposed transaction and the CVR structure are compelling from a strategic and financial standpoint. The acquisition of Monogram further strengthens Zimmer Biomet&#8217;s robotics capabilities.
Zimmer Biomet expects the acquisition will contribute to revenue growth in 2027 and beyond by improving the company&#8217;s robotic knee adoption in the U.S., increasing the share of wallet through reaching new customers with a broader product range, and expanding the company&#8217;s industry-leading global knee offerings.
Zimmer Biomet anticipates the acquisition will be neutral to adjusted earnings per share in 2025, 2026, and 2027 and accretive in 2028 and beyond.
Additionally, the transaction is projected to generate a high-single-digit return on invested capital (ROIC) by year five, with an increasing contribution thereafter.
Price Action: MGRM stock is up 60.2% at $5.27, and ZBH stock is up 0.09% at $93.87 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46388874/eu-prepares-24-5b-in-tariffs-as-trump-threatens-30-import-tax-on-mexico-europe" target="_blank" rel="noreferrer noopener">EU Prepares $24.5B In Tariffs As Trump Threatens 30% Import Tax On Mexico, Europe</a></li>
</ul>
Photo via Shutterstock

Large Cap

News

Health Care

Movers

General

MGRM

Zimmer Biomet To Lead Orthopedic Robotics With Monogram's AI Tech

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/07/11/final-trades-uber-delta-zimmer-holdings-and-boeing.html">Halftime Report Final Trades</a>,&#8221; Stephanie Link, chief investment strategist and portfolio manager at Hightower, picked The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) as her final trade.
The Federal Aviation Administration (FAA) and Boeing have both said that the fuel switch locks on the 787-Dreamliner aircraft are safe in the aftermath of the Air India crash in India's Ahmedabad in Gujarat state last month.
Boeing has long <a href="https://www.npr.org/2024/01/19/1225466035/boeing-737-max-faa-door-plug-alaska-crashes-ntsb">benefited</a> from having close ties with the U.S. government. This year, the Trump administration, alongside Boeing CEO Kelly Ortberg, announced a major aircraft deal with Qatar Airways, initially claiming it was worth $200 billion — a figure later revised to $96 billion. However, experts estimate the real value is under $30 billion after industry discounts. The deal includes 130 Boeing 787s and 30 777X jets, with options for 50 more, and was described as Boeing's <a href="https://www.benzinga.com/government/regulations/25/05/45446924/trump-secures-12-trillion-qatar-deal-as-boeing-ge-land-record-orders">largest-ever widebody aircraft sale</a>.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, named Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) as <a href="https://www.benzinga.com/quote/UBER/analyst-ratings">his final trade</a>.
Supporting his view, JPMorgan analyst Doug Anmuth maintained Uber with an Overweight rating and raised the price target from $105 to $110.
Jim Lebenthal, partner at Cerity Partners, picked Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) as his final trade.
Lending support to his choice, Delta Air Lines, on July 10, posted stronger-than-expected second-quarter results and reinstated its full-year 2025 guidance.
Jenny Van Leeuwen Harrington, Chief Executive Officer of Gilman Hill Asset Management, LLC, named Zimmer Biomet Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) as her final trade.
On the earnings front, Zimmer Biomet Holdings, will release its second quarter earnings on Thursday, Aug. 7. Analysts expect the company to report quarterly earnings at $1.98 per share on revenue of $2.06 billion.
Price Action:
<ul class="wp-block-list">
<li>Uber shares fell 1.1% to close at $95.39 on Friday.</li>
<li>Delta Air Lines fell 0.2% to close at $56.65 during the session.</li>
<li>Zimmer Biomet shares slipped 1.4% to close at $93.79.</li>
<li>Boeing shares gained 0.3% to close at $226.84 during the session.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46364472/top-3-real-estate-stocks-that-may-fall-off-a-cliff-this-month">Top 3 Real Estate Stocks That May Fall Off A Cliff This Month</a></li>
</ul>
Image: Shutterstock

Markets

Media

Trading Ideas

UBER

Boeing, Uber, Delta Air Lines And A Health Care Stock On CNBC's 'Final Trades'

Zimmer Biomet Says 'Acquisition expected to be neutral to adjusted earnings per share in 2025 – 2027 and accretive thereafter and to contribute to revenue growth beginning in 2027'

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Monogram Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>), an orthopedic robotics company, today announced they have entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of stock of Monogram for an upfront payment of $4.04 per share in cash, corresponding to an equity value of approximately $177 million and an enterprise value of approximately $168 million. Monogram common stockholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share of common stock in cash if certain product development, regulatory and revenue milestones are achieved through 2030. The respective boards of directors of Zimmer Biomet and Monogram have unanimously approved the proposed transaction.

Zimmer Biomet To Acquire Monogram Technologies For $4.04/Share; Monogram Shareholders To Also Receive CVR Entitling Holder To Receive Up To $12.37/Share OF Stock In Cash If Certain Milestones Are Achieved Through 2030

Analyst Ratings

CNBC Halftime Report Final Trades: Uber Technologies, Zimmer Biomet, Boeing, Delta Air Lines

Ratings for Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Zimmer Biomet Holdings, revealing an average target of $106.36, a high estimate of $125.00, and a low estimate of $95.00. Experiencing a 13.01% decline, the current average is now lower than the previous average price target of $122.27. 
<img src="https://www.benzinga.com/files/images/story/2025/1751983250_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Zimmer Biomet Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$96.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$101.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$104.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$98.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zimmer Biomet Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zimmer Biomet Holdings compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Zimmer Biomet Holdings's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Zimmer Biomet Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ZBH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Zimmer Biomet Holdings analyst ratings.</a>
<h2>All You Need to Know About Zimmer Biomet Holdings</h2>
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
<h3>Zimmer Biomet Holdings's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Zimmer Biomet Holdings showcased positive performance, achieving a revenue growth rate of 1.05% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.53%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Zimmer Biomet Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of 1.46%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Zimmer Biomet Holdings's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.84%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Zimmer Biomet Holdings's debt-to-equity ratio is below the industry average. With a ratio of 0.58, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Zimmer Biomet Holdings: 11 Analysts Share Their Views

Evercore ISI Group analyst Vijay Kumar maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a In-Line and lowers the price target from $102 to $96.

Price Target

Evercore ISI Group Maintains In-Line on Zimmer Biomet Holdings, Lowers Price Target to $96

Zimmer Biomet Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) short percent of float has risen 16.61% since its last report. The company recently reported that it has 6.42 million shares sold short, which is 3.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.65 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Zimmer Biomet Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751043628_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zimmer Biomet Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Zimmer Biomet Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Zimmer Biomet Holdings's peer group average for short interest as a percentage of float is 5.20%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Zimmer Biomet Holdings's Recent Short Interest

Treace Medical Concepts, Inc.&nbsp;("Treace" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship&nbsp;<a href="https://www.globenewswire.com/Tracker?data=PhrvPgwWnFGurg6S4cTMXPnZSvIbsh-7vD75qshZf4W2Rv0eH6iYS-TAky5-84_Ri0VIN7nTuV0z-GkegYiluBakImmk3Zj1w4rROHMt6lwsw3REO81rw-etukNCmXZSin4tSCCkNkE0xBHrq0Q7tPjokuA-oap_BjbHuXsRo-LgNNZoGsnUePUbT2-ILzChf2DHLwrSQXQZyWVQvrJEbk0AQHM7eVsk7zC4vaKtqUoeoDHCJzOqPhWKcqtvWnTInYG_aeXX0i81qxfMgqiVsg==">Lapiplasty</a><a href="https://www.globenewswire.com/Tracker?data=LrnJlF18b7EWzk_EAUJaWxGrxsoWgQpX1WKeJ0MipgVBshUVXHUA5zPh5NCDgcNKBO6A9xD35YFbiyZ1DNTulkO1cYzusFeKbXuLEM4blCZJ5k744h9h6kzAVfgox0FPgavIE7DwiF422KNrSWJFHx01V7TfoKgoah7rt5AC07IhZmYAf7CbRDc1QqTt8wwbr56hBQaud9XD_58LlCi_nMcPOnTeqG5Lb_IyWD8AxttJPAbLBRIxrVfgQTACvnytyRl4MFQiNTFTY4mRBRbg-Q==">&#xAE;</a>&nbsp;and&nbsp;<a href="https://www.globenewswire.com/Tracker?data=Ky8kGGLXsMTu3wsAXQppn1PfeewfClEbXAZbmmoTmTGzckwETGDKjrRCVtjW_PfjE682okBcjHwSpyYD3ZLTWqlyvmlQaTncmuRanfcgyPXq89flAjVvT8U90c9JXN3ZHl_RVYLNeeXD1fy3lK0reILVhp40trP0SNtWir-Im2LoRiGF6hZmEkTIaoQWpTaJNiiAU3_p36gcE7q72b6FYhsIHMJpXu4rMIRqg6AB3B4p9xhKAjU7aR8hF3ED29goR3-pfMcJotTJpuPXNubY4swADMFv4kvo1u9e-PuH6H034oUlBGOBo8pbqcqr6pHY">Adductoplasty</a><a href="https://www.globenewswire.com/Tracker?data=iU3fmGaUZi_JeR470Lioedud-n-0b_bx4qOO-3b22Rvo4Xdt1yz_PqYHunQivstC8HxZtcFDnANwN5nPFT05HigJ0nSJBwn0LnMVL0ugniZAkJRYpK-63l0Qn7aWa0elJwsd5hZielGaxqcGOfBP6MtE2xeJMav5md3UhP8ioZkA0CQNWbieFy6sUjXGNl9yCVNuhlpeg58_DWgp2zGQCrNi8j1JTY2kOFmxR0GJ6TFclq7OrROrzjUrDqYhpUNd3NzdJg9mJf7bHMrBObB4dtCB4BQHRme_eeVBW5QPZ4w=">&#xAE;</a>&nbsp;procedures, today announced that it filed a lawsuit against&nbsp;Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, "Zimmer") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>), alleging infringement of 4 patents related to Treace's innovative Lapiplasty&#xAE; 3D Bunion Correction&#xAE; technologies. The suit was filed in the&nbsp;United States District Court for the District of Delaware, and seeks injunctive relief and damages.

Biotech

TMCI

Treace Medical Concepts Files Patent Infringement Lawsuit Against Zimmer Biomet And Paragon 28, Alleging Violation Of 4 Patents Related To Its Lapiplasty 3D Bunion Correction Technologies And Seeking Injunctive Relief And Damages

Zimmer Biomet Appoints Kevin Thornal As Group President, Global Businesses And Americas, Effective July 1, 2025

Ratings for Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $107.4, a high estimate of $125.00, and a low estimate of $95.00. A 13.6% drop is evident in the current average compared to the previous average price target of $124.30. 
<img src="https://www.benzinga.com/files/images/story/2025/1747058418_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Zimmer Biomet Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$101.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$104.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$98.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zimmer Biomet Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Zimmer Biomet Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Zimmer Biomet Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Zimmer Biomet Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ZBH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Zimmer Biomet Holdings analyst ratings.</a>
<h2>All You Need to Know About Zimmer Biomet Holdings</h2>
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
<h3>Unraveling the Financial Story of Zimmer Biomet Holdings</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Zimmer Biomet Holdings's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.05% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zimmer Biomet Holdings's net margin is impressive, surpassing industry averages. With a net margin of 9.53%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Zimmer Biomet Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of 1.46%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.84%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.58, Zimmer Biomet Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Zimmer Biomet Holdings: Insights From 10 Financial Analysts

Canaccord Genuity analyst William Plovanic maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Hold and lowers the price target from $115 to $101.

Canaccord Genuity Maintains Hold on Zimmer Biomet Holdings, Lowers Price Target to $101

JMP Securities analyst David Turkaly maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Market Outperform and lowers the price target from $140 to $125.

JMP Securities Maintains Market Outperform on Zimmer Biomet Holdings, Lowers Price Target to $125

Zimmer Biomet Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) reported better-than-expected earnings for the <a href="https://www.benzinga.com/quote/ZBH">first quarter on Monday</a>.
The company posted first-quarter adjusted EPS of $1.81, down from $1.94 a year ago, beating the Street estimates of $1.77. The orthopedic giant reported sales of $1.91 billion, up 1.1% on a reported basis (+2.3% on constant currency), almost in line with the consensus of $1.9 billion.
&#8220;We are proud of our team&#8217;s continued execution and performance to start the year, as we delivered solid first quarter results and advanced our bold innovation agenda,&#8221; said Ivan Tornos, Zimmer Biomet&#8217;s President and Chief Executive Officer.
The company expects fiscal year 2025 adjusted EPS of $7.90-$8.10, down from prior guidance of $8.15-$8.35 versus consensus of $8.19.
The company expects 2025 revenue growth of 5.7% – 8.2% compared to 1%-3.5% expected earlier. It expects a foreign currency exchange impact of 0.0%-0.5%.
Zimmer Biomet shares gained 0.7% to trade at $91.08 on Tuesday.
These analysts made changes to their price targets on Zimmer Biomet following earnings announcement.
<ul>
<li>Baird analyst Jeff Johnson maintained Zimmer Biomet Holdings with an Outperform rating and lowered the price target from $130 to $115.</li>
<li>Wells Fargo analyst Larry Biegelsen maintained the stock with an Equal-Weight rating and lowered the price target from $113 to $98.</li>
<li>JP Morgan analyst Robbie Marcus maintained the stock with an Overweight rating and lowered the price target from $128 to $105.</li>
<li>Morgan Stanley analyst Cecilia Furlong maintained the stock with an Equal-Weight rating and lowered the price target from $115 to $95.</li>
<li>RBC Capital analyst Shagun Singh maintained Zimmer Biomet with an Outperform and lowered the price target from $125 to $112.</li>
<li>Stifel analyst Rick Wise maintained Zimmer Biomet with a Buy and lowered the price target from $138 to $115.</li>
<li>Raymond James analyst Jayson Bedford maintained Zimmer Biomet with an Outperform rating and lowered the price target from $119 to $104.</li>
<li>Goldman Sachs analyst David Roman maintained the stock with a Neutral and lowered the price target from $120 to $104.</li>
</ul>
Considering buying ZBH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="619" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06142102/image-56-1024x619.png" alt="" class="wp-image-904113" style="width:549px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06142102/image-56-1024x619.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06142102/image-56-300x181.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06142102/image-56-768x464.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06142102/image-56.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Earnings

These Analysts Lower Their Forecasts On Zimmer Biomet After Q1 Results

Goldman Sachs analyst David Roman maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Neutral and lowers the price target from $120 to $104.

Goldman Sachs Maintains Neutral on Zimmer Biomet Holdings, Lowers Price Target to $104

Raymond James analyst Jayson Bedford maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Outperform and lowers the price target from $119 to $104.

Raymond James Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $104

Stifel analyst Rick Wise maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Buy and lowers the price target from $138 to $115.

Stifel Maintains Buy on Zimmer Biomet Holdings, Lowers Price Target to $115

RBC Capital analyst Shagun Singh maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Outperform and lowers the price target from $125 to $112.

RBC Capital Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $112

Morgan Stanley analyst Cecilia Furlong maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a Equal-Weight and lowers the price target from $115 to $95.

Morgan Stanley Maintains Equal-Weight on Zimmer Biomet Holdings, Lowers Price Target to $95

Zimmer Biomet Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) short percent of float has fallen 11.44% since its last report. The company recently reported that it has 6.28 million shares sold short, which is 3.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.36 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Zimmer Biomet Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746543621_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zimmer Biomet Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Zimmer Biomet Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Zimmer Biomet Holdings's peer group average for short interest as a percentage of float is 4.18%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Zimmer Biomet Holdings?

Press Releases

PARAGON 28 INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Paragon 28, Inc. - FNA

Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financial Results

Zimmer Biomet Completes Acquisition of Paragon 28

Zimmer Biomet Announces First Quarter 2025 Financial Results

Zimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas

Dividends

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025

Legal

Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2025 Financial Results

Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Comments

Zimmer Biomet Holdings

Intérêt court

Zimmer Biomet Holdings (NYSE:ZBH) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL